Cyclononylhydrazine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cyclononylhydrazine
• 英文别名: cyclononylhydrazine
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: FBWWUKULLQCEGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021188696A1

  公开（公告）日：2021-09-23

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20190330193A1

  公开（公告）日：2019-10-31

  Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]: wherein R 1 is hydrogen or halogen, R 2 is C 1-6 alkyl or halo-C 1-6 alkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.

  揭示了具有SGLT1抑制活性的以杂环芳基取代的吡唑化合物或其药学可接受的盐，用作药物，包括它们的药物组合物，以及其药用。具体地，提供了以下式[X]的化合物：其中R1为氢或卤素，R2为C1-6烷基或卤代C1-6烷基，环Het为取代的吡啶基或可选择取代的吡嗪基、嘧啶基或吡啉基，或其药学可接受的盐，包括它的药物组合物和药用。
• Methods of preparing Tecovirimat
  申请人：SIGA TECHNOLOGIES, INC.

  公开号：US10029985B2

  公开（公告）日：2018-07-24

  Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

  本发明公开了用于治疗或预防病毒感染和相关疾病，特别是由正痘病毒引起的病毒感染和相关疾病的特考韦瑞马特的制备方法。
• Methods of preparing tecovirimat
  申请人：SIGA TECHNOLOGIES, INC.

  公开号：US10662155B2

  公开（公告）日：2020-05-26

  Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

  本发明公开了用于治疗或预防病毒感染和相关疾病，特别是由正痘病毒引起的病毒感染和相关疾病的特考韦瑞马特的制备方法。
• Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
  申请人：Japan Tobacco Inc.

  公开号：US10988462B2

  公开（公告）日：2021-04-27

  Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]: wherein R1 is hydrogen or halogen, R2 is C1-6 alkyl or halo-C1-6 alkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.

  本发明公开了具有 SGLT1 抑制活性并可用于药物的杂芳基取代的吡唑化合物或其药学上可接受的盐，以及包含这些化合物的药物组合物及其药物用途。具体地说，一种式[X]的化合物： 其中 R1 是氢或卤素，R2 是 C1-6 烷基或卤代-C1-6 烷基，环 Het 是取代的吡啶基或任选取代的吡嗪基、嘧啶基或哒嗪基，或其药学上可接受的盐、由其组成的药物组合物及其药物用途。